Minimally differentiated acute myeloid leukemia (AML-M0
Introduction
The French-American-British (FAB) classification 1-3 minimally differentiated or M0 acute leukemia (AML-M0) is characterized by undifferentiated morphology by light microscopy, expression of immaturity (CD34 or CD7) and myeloid (CD13 or CD33) markers, 2,4-8 the latter permitting differentiation of AML-M0 from 'stem cell' acute leukemia. 9 Low remission rate and frequent relapses contribute to the short survival observed in this subtype. 2, 4, 10 The reason for this remarkably poor prognosis is not elucidated, but the convergence of unfavorable prognostic factors has been proposed. High incidence of cytogenetic abnormalities and expression of multidrug-resistance P-glycoprotein may explain the poor sensitivity of leukemic cells to chemotherapy. 5, 10 Escape from immune recognition can contribute to AML prognosis, since immune response has an important role in the control of 'minimal residual disease' as outlined by the allogeneic stem cell transplantation-associated 'graft-versus-leukemia' reaction. [11] [12] [13] Lack of differentiation may contribute to the presence of a large population of leukemic cells capable of sustaining self-renewal and proliferation, which recently has been demonstrated to be contained in the CD34 +
/CD38
+ blast subpopulation. [14] [15] [16] [17] [18] [19] To gain more insight into AML-M0 physiopathology, we analyzed in vitro alloimmune recognition and adhesion/ constimulatory molecule expression in AML-M0, together with the frequency of CD34
− leukemic progenitors, in comparison with more differentiated blasts from myelo/monocytic leukemias or non-leukemic hematopoietic progenitors from different patients.
Materials and methods

Patient samples
Peripheral blood samples, obtained before specific anti-leukemic therapy and after informed consent by the patient, were part of diagnostic procedures. We analyzed nine patients with AML-M0, 23 patients with more differentiated AMLs, and three patients with non-hematopoietic cancers (for the analysis of granulocyte colony-stimulating factor (G-CSF)-mobilized hematopoietic progenitors). Diagnosis was established following FAB classification 1 and specific recommendations for AML-M0 distinction: 2, 3, 10, 20 (1) negativity of light microscopy myeloperoxidase and Sudan black-B or positivity in less than 3% of blasts; (2) negative lymphoid markers (positive terminal deoxynucleotydil transferase or CD7 were accepted); (3) positive CD13 and/or CD33. Slides were independently reviewed by two morphologists (DS and CA).
Cell separation
Peripheral blood mononucleated cells (PBMCs) from healthy donors and leukemic patients were isolated on FicollHypaque gradients and viably frozen in liquid nitrogen until use. 21 Regarding leukemic cells, samples with a blast fraction lower than 95% were purified by negative selection using magnetic beads coated with anti-CD3, anti-CD19 and, depending on the phenotype at diagnosis, anti-CD56 and/or anti-CD14 mAbs (Beckman Coulter, Marseille, France). For mixed leukocyte culture against leukemic cells, responding T lymphocytes were purified by sheep erythrocyte rosetting plus overnight adhesion in plastic dishes. 21 Non-leukemic hematopoietic progenitors were obtained after G-CSF mobilization from patients with non-hematological malignancies. The CD34
+ preparation was performed using the MACS column isolation kit (Tebu, Le Perray-en-Yvelines, France). In all cases, the purity of the preparation (Ͼ95%) was assessed by flow cytometry analysis and Giemsa staining of cytocentrifuge preparations.
Flow cytometry
Cell 
Primary mixed lymphocyte-tumor reaction (MLTR) and cytokine production
Culture experiments were performed in RPMI 1640 (BioWhittaker, Walkersville, MD, USA) with 10% fetal bovine serum, 1% l-glutamine (Life Technologies, Gaithersburg, MA, USA), 1% Na pyruvate (Life Technologies) and 5 × 10 −5 ␤-mercaptoethanol (Sigma Chemical, St Louis, M0, USA). Leukemic cells had ␥-irradiation at 50 Gy and were then incubated (5 × 10 4 per well) with allogeneic T lymphocytes (5 × 10 4 per well). Supernatants were harvested after a 5-day incubation, and IL-2 was tested using an immunoenzymatic assay with a sensitivity of 5 pg/ml (Immunotech). The T lymphocyte proliferation was assessed after 6 days of culture by an 3 H-thymidine (Amersham, Buckinghamshire, UK) pulse performed for the 10 last h. Thymidine incorporation was assessed with a direct beta counter (Matrix 9600; Packard Instruments, Rungis, France).
Cell lines and co-incubation conditions
The L cell stable transfectants for human CD40L and CD32 expression were kindly provided by Dr J Banchereau (Schering-Plough, Lyon, France). Leukemic blasts (5 × 10 6 per well) were pre-incubated for 48 h with transfected cells (5 × 10 5 per well) and then separated for further experiments. The ␥-IFN (kind gift of Roussel-Uclaf, Paris, France) was used at 20 IU/ml.
Statistical analysis
Statistical analysis was performed using the SPSS software. 22 The Kolmogorov-Smirnov test was used to determine if the data fitted a normal distribution. As this test rejected the assumption of normality for all variables, comparisons were made using the non-parametric Wilcoxon matched-pairs signed-rank test.
Results
Interleukin-2 secretion by allogeneic responding lymphocytes in MLTR against AML-M0
We tested the immunogenicity of highly purified AML-M0 blasts as evaluated in MLTR via IL-2 secretion by allogeneic responding T lymphocytes ( Figure 1 ). The mean IL-2 secretion was significantly lower in MLR against AML-M0 (128 ± 95 pg/ml, P Ͻ 0.05) as compared with MLR against 23 differentiated control AMLs (304 ± 159 pg/ml) or 'standard' MLR of T lymphocytes against unrelated T lymphocytes (402 ± 37 pg/ml). No IL-2 secretion was detected in control unstimulated T lymphocytes. No IL-2 was detected in supernatants of leukemic blasts cultured alone (data not shown).
Comparative expression of immune-recognition molecules
We evaluated the expression of adhesion/costimulatory molecules which are considered to be central to the development of efficient immune recognition (MHC class I and class II DR molecules, ICAM-1, LFA-3, B7-1, B7-2 and CD40) in AML-M0 in comparison with 20 more differentiated AMLs (M1 to M5), as seen in Table 1 . The MHC class 1 molecules were expressed in comparable percentages of leukemic cells in AML-M0 and differentiated AMLs, but with moderately increased MF1 (P Ͻ 0.1) in differentiated AMLs. The MHC class II DR molecules were expressed in a lower percentage of leukemic cells in AML-M0 in comparison with more differentiated AMLs (P Ͻ 0.05), while no significant difference was observed regarding the MFIs. A comparable expression of ICAM-I and LFA-3 was observed in AML-M0 and more differentiated AMLs both regarding the mean percentage of positive
Figure 1
Interleukin-2 secretion by allogeneic T lymphocytes in mixed leukocyte culture against leukemic cells. Leukemic cells were irradiated (50 Gy), mixed with allogeneic T lymphocytes at stimulator/responder ratio of 1:1. The IL-2 secretion was evaluated at day 5. For AML-M0, results represent the mean of 27 experiments (nine leukemias tested against T lymphocytes from three different allogeneic unrelated donors). For control non-M0 AMLs, results represent 23 experiments (23 differentiated AMLs each tested once with different T lymphocytes from one of the three unrelated donors). 'Standard' MLR represents the alloreactivity of T lymphocytes against unrelated T lymphocytes, and corresponds to six experiments (three different sets of T lymphocyte tested in duplicate). Negative control corresponds to spontaneous IL-2 release by unstimulated T lymphocytes from the three unrelated donors tested in duplicate. No IL-2 secretion was detected in supernatants of leukemic blast cultured alone (data not shown). 
Regulation of adhesion/costimulatory molecules and of alloimmune recognition of leukemic cells by ␥-IFN and stimulation via CD40
We wanted to test the effects of ␥-IFN and CD40 stimulation on AML-M0 (Figure 2 ), since these stimuli have significant effects on adhesion/costimulatory molecule expression and Analysis of adhesion/costimulatory molecules in AML-M0 in comparison with more differentiated AMLs. The expression of MHC class I and II DR molecules, ICAM-1, LFA-3, B7-1, B7-2 and CD40 was performed by double staining of leukemic cells using a leukemic marker (either CD13 or CD33 for AML-M0, or adapted markers for the other FAB subtypes) and the marker studied. Black bars correspond to ␥-IFN stimulation as expressed by the difference of MFI between ␥-IFN stimulated blasts and the control represented by medium alone (␥-IFN − control). White bars correspond to CD40 stimulation as expressed by the difference of MF1 between CD40L-transfected fibroblast-stimulated and the control CD32-expressing fibroblast-stimulated leukemia cells (CD40L − CD32). Data are represented as the mean of the MFI ± standard deviation, in all cases after subtraction of the background represented by the corresponding isotypic control.
immune recognition in terminally differentiated blasts. 23 We used CD32-expressing fibroblasts as the control for CD40L, and ␥-IFN pre-incubation as comparison since this cytokine is an efficient inducer of immune-recognition molecules, and B7-2 in particular, in normal monocytes 24, 25 or AML cell lines. 26 The efficiency of the stimulation was evaluated by calculating the MFI differences (␥-IFN − medium) or (CD40L − CD32). A more potent (P Ͻ 0.05) induction of MHC class I molecules was obtained after blast cell incubation with ␥-IFN (mean MFI increase 383 ± 163, P Ͻ 0.05) than after CD40 stimulation via CD40L-transfected fibroblasts (mean MFI increase 118 ± 59, P Ͻ 0.05). Both the ␥-IFN stimulation (mean MFI increase 102 ± 52, P Ͻ 0.1) and CD40L cells (mean MFI increase 135 ± 20, P Ͻ 0.1) obtained a significant induction of MHC class II DR molecules, which was not significantly different between these two different stimuli. Regarding LFA-3, ␥-IFN stimulation did not obtain a significant up-regulation (mean MFI increase 6.5 ± 7) while CD40L cells attained significant induction level (mean MFI increase 37 ± 15, P Ͻ 0.1). While ␥-IFN poorly induced ICAM-1 expression (mean MFI increase 25 ± 42), a significant increase was observed in CD40L cells (mean MFI increase 244 ± 27, P Ͻ 0.1). Stimulation via ␥-IFN failed to significantly induce B7-1 expression (mean MFI increase 8 ± 11), while a higher induction (mean MFI increase 20 ± 13, P Ͻ 0.1) was observed following CD40L cell incubation, where the absolute value was low but significant due to the very weak baseline expression. Finally, both the ␥-IFN stimulation (mean MFI increase 55 ± 19, P Ͻ 0.1) and CD40L cells (mean MFI increase 241 ± 56, P Ͻ 0.1) obtained a significant induction of B7-2, which was significantly higher for CD40L (P Ͻ 0.1). As a control of the efficiency of our CD40 stimulation system, two non-Hodgkin lymphomas showed a very potent up-regulation of all tested molecules after CD40L cell incubation (data not shown). Results regarding the percentage of positive cells were stable or paralleled MFI increase (data not shown).
We further tested the effect of leukemic blast cell pre-stimulation with ␥-IFN or via CD40 regarding their alloimmune recognition by normal T lymphocytes, as evaluated by T cell IL-2 secretion (Table 2 ). Both ␥-IFN (P Ͻ 0.05) and stimulation via CD40 (P Ͻ 0.5) induced increased secretion of IL-2 by responding T lymphocytes. These results were comparable with those obtained with differentiated AMLs.
Measure of the CD34
+ /CD38 − leukaemia progenitor cell population
We performed double staining on the gated blast population with anti-CD34 and anti-CD38 mAbs. The mean percentage Table 2 Fold induction of IL-2 secretion by responding allogenic T lymphocytes in mixed lymphocyte-tumor reaction against leukemic cells pre-stimulated by ␥-IFN or CD40
Leukemic blasts were incubated for 48 h in medium alone, or with ␥-IFN, CD32-transfected or CD40L-transfected fibroblasts. Then, blasts were washed and separated from fibroblasts, and a mixed lymphocyte-tumor reaction was performed as described in Materials and methods. Data are presented as the mean fold induction of IL-2 secretion ± standard deviation (s.d.), from experiments performed in duplicate with seven AML-M0 and six control differentiated AMLs. The fold induction is calculated by the ratio stimulus/control, ie incubation of blasts in medium alone corresponding to ␥-IFN control, and CD32-expressing fibroblasts as the control for stimulation with CD40L-transfected fibroblasts.
of CD34
− cells in the whole blast cell population of the six tested AML-M0 (Figure 3 , first two rows) was 40 ± 30, as compared to 2.5 ± 2 in the 10 more differentiated AMLs (M1 to M5) we tested ( Figure 3 , third row for three representative samples). The percentage of CD38
− expression was tested in control G-CSF-mobilised highly purified CD34
+ non-leukemic hematopoietic precursors (Figure 3 , last row, three different donors); the CD38 − fraction corresponded to 1.8% ± 0.8 of the CD34 + haematopoietic precursors.
Figure 3
Expression of CD34 and CD38 in AML cells by multivariate flow cytometry analysis. Viable cells were gated according to their side and forward light scatter characteristics to distinguish a blast myeloid gate (data not shown). We tested six out of the nine undifferentiated AML-M0 (first two rows), which were compared to 10 more differentiated AMLs (M1-M5) of which three representative samples are shown (third row) and to non-leukemic CD34
+ G-CSF-mobilised progenitors from three different patients with no hematological malignancies (fourth row).
Discussion
Recently, the anti-leukemic effect of donor lymphocyte infusions has been attributed more specifically, at least in chronic myeloid leukemia, to the recognition of CD34 + leukemia progenitors. 27 The positivity of leukemic cells for CD34, a marker of hematopoietic stem cells, is common in AML-M0, M1 or M7, and rarely seen in AML-M2 to M5. 8, 28, 29 The high percentage of CD34 + leukemic precursors in the AML-M0 leukemia model allowed us to test their differential immune recognition in comparison with more differentiated blasts.
The first significant observation in our study was that AML-M0 leukemic cells elicit a weaker immune response in MLR than more differentiated AMLs. This is in line with their decreased MHC class II DR expression and, more particularly, with defective expression of B7-2, a molecule of pivotal importance for IL-2 secretion in MLTR against AMLs. 23 A lower expression of MHC class I molecules was also observed in AML-M0, which could contribute to impaired development of specific cytotoxicity. These data correlate with physiology since 'normal' hematopoietic CD34
+ precursors capable of stimulating allogeneic reaction are contained in the B7-2-positive subpopulation. 30, 31 This may suggest that the decreased alloimmune stimulation potential of AML-M0 originates from a physiological mechanism devoted to the protection of normal hematopoietic stem cells against inappropriate immune reactions, which, alternatively, could impair the anti-leukemia immune response and thus contribute to tumour escape from immune surveillance. 32 Nonetheless, we demonstrate that stimulation of blast cell by both ␥-IFN and CD40 can increase the alloimmune properties of AML-M0 blasts, probably via increased expression of adhesion/costimulatory molecules. This suggests interesting clues for experimental immunotherapy, since nonconventional therapy needs to be developed in this subtype of very poor prognosis. The role of CD40 stimulation in cancer immunotherapy is nonetheless still debated, 33 and very few data are available regarding AMLs. 23 We excluded a direct proliferative effect of CD40 stimulation in AML-M0 (data not shown), but additional data and animal models are required to better define the role of CD40 stimulation in leukemia immunotherapy. Other cytokines have also to be tested in AML-M0, such as IL-7, a cytokine that plays a role in the regulation of the alloimmune recognition properties of differentiated AMLs. 34 Evidence has accumulated for malignant transformation at the early hematopoietic stem cell compartment, ie CD34 + cells lacking CD33 and CD38. 17, 18 These cells are characterized by extensive in vitro proliferative capacities under adequate culture conditions. 19 In vivo, CD34 + /CD38 progenitors are able to efficiently engraft SCID mice, to differentiate in leukemic blasts and to sustain their self-renewal, 14 ,15 thus defining a cell initiating human AML. The third important observation of our study was the unexpectedly high percentage of CD34 + /CD38
− leukemic cells in AML-M0, corresponding to the PI differentiation stage defined by Terstappen et al. 35 In AML-M7, another rare FAB subtype of poor prognosis, the CD34 + leukemic cells also lack CD38, but the CD34 + /CD38 subset represents a less important blast fraction than in M0. 29 Our observations in AML-M0 contrast with data we obtained in differentiated AMLs (р2.5%) or from the literature. 15 Moreover, CD38 expression in the CD34 + AML-M0 blast subset is also in sharp contrast with non-leukemic CD34 + hematopoietic progenitors which are mostly CD38 + . This suggests a quite early maturation blockade specific for the AML-M0 subtype. As a consequence, most AML-M0 correspond to cate-gory 1 or 2 of the differentiation pathway-based classification of Terstappen et al. 35 Patients in the 1 and 2 categories have a significantly worse prognosis than more 'differentiated subtypes' with lower complete remission rate, shorter event-free survival and overall survival, 35 in line with the survival advantage observed by some authors for CD34-negative acute leukemias. [36] [37] [38] One hypothesis among others to explain this unfavorable prognosis could be a higher resistance of more immature progenitor cells to chemotherapy. This could be linked to a higher number of quiescent G 0 phase cells, in line with the difference observed between normal CD34 + /CD38 (most quiescent) and CD34 + /CD38
+ (25% cycling cells) hematopoietic progenitors. 35 
